Merck Fosamax Study Shows Benefit Vs. Actonel; Aventis/P&G Fault Endpoint
Executive Summary
A Merck head-to-head trial showing an efficacy advantage for its osteoporosis agent Fosamax versus Actonel is "misleading" because the claim is based on bone mineral density rather than the preferred fracture risk endpoint, competitors maintain
You may also be interested in...
Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose
Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen
Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose
Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen
Merck Sales Force More Focused, Not Smaller, After Vioxx Withdrawal
Merck sales reps will detail fewer products to fewer doctors under a reorganized structure, the company told analysts during its investor day Dec. 14